Results about: colon cancer

Researchers at IRB discover a key regulator of colon cancer

The team headed by Angel Rodríguez Nebreda, ICREA researcher at IRB, identifies for the first time in mice that the p38 MAPK protein is required for the survival and proliferation of colon cancer cells.

In the same study the scientists demonstrate that a p38 inhibitor that has been used in clinical trials for inflammatory diseases shrinks the tumours in mice.

The study, published today in Cancer Cell, has received funding from the BBVA Foundation, the European project InflaCare, the Spanish Government, and the European Research Council (ERC).

SUPPRESSTEM, five institutes and pharmaceutical companies join forces against cancer

Each year about 330,000 Europeans are diagnosed with colorectal cancer, a disease with a mortality rate of 44%. Many of the new treatments fail in clinical assays, and colorectal cancer metastasis is largely incurable

Amongst the best in cancer and metastasis studies

The journal Cancer Cell ranks the article on colon cancer metastasis by Eduard Batlle and Elena Sancho among the best 10 in 2012.

The Botín Foundation announces support for two IRB Barcelona business projects

• The “Mind the Gap” programme selects Eduard Batlle and Elena Sancho to develop a diagnostic kit for patients at risk for metastasis, and Modesto Orozco to create a drug design platform.

• The IRB Barcelona projects, two of the three chosen by the Foundation, will receive one million euros of funding as well as management, coordination and consulting support for two years.

• An international committee of experts in investment strategies for biotechnology and biomedicine praise the high potential for innovation and viability of the projects.